{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:44:07Z","timestamp":1790664247435,"version":"4.1.0"},"reference-count":99,"publisher":"BMJ","license":[{"start":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T00:00:00Z","timestamp":1540425600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the efficacy, effectiveness, and safety of the herpes zoster live attenuated vaccine with the herpes zoster adjuvant recombinant subunit vaccine or placebo for adults aged 50 and older.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic review with bayesian meta-analysis and network meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>Medline, Embase, and Cochrane Library (inception to January 2017), grey literature, and reference lists of included studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria for study selection<\/jats:title>\n                    <jats:p>Experimental, quasi-experimental, and observational studies that compared the live attenuated vaccine with the adjuvant recombinant subunit vaccine, placebo, or no vaccine in adults aged 50 and older. Relevant outcomes were incidence of herpes zoster (primary outcome), herpes zoster ophthalmicus, post-herpetic neuralgia, quality of life, adverse events, and death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>27 studies (22 randomised controlled trials) including 2\u2009044\u2009504 patients, along with 18 companion reports, were included after screening 2037 titles and abstracts, followed by 175 full text articles. Network meta-analysis of five randomised controlled trials found no statistically significant differences between the live attenuated vaccine and placebo for incidence of laboratory confirmed herpes zoster. The adjuvant recombinant subunit vaccine, however, was statistically superior to both the live attenuated vaccine (vaccine efficacy 85%, 95% credible interval 31% to 98%) and placebo (94%, 79% to 98%). Network meta-analysis of 11 randomised controlled trials showed the adjuvant recombinant subunit vaccine to be associated with statistically more adverse events at injection sites than the live attenuated vaccine (relative risk 1.79, 95% credible interval 1.05 to 2.34; risk difference 30%, 95% credible interval 2% to 51%) and placebo (5.63, 3.57 to 7.29 and 53%, 30% to 73%, respectively). Network meta-analysis of nine randomised controlled trials showed the adjuvant recombinant subunit vaccine to be associated with statistically more systemic adverse events than placebo (2.28, 1.45 to 3.65 and 20%, 6% to 40%, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Using the adjuvant recombinant subunit vaccine might prevent more cases of herpes zoster than using the live attenuated vaccine, but the adjuvant recombinant subunit vaccine also carries a greater risk of adverse events at injection sites.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Protocol registration<\/jats:title>\n                    <jats:p>Prospero CRD42017056389.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmj.k4029","type":"journal-article","created":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T12:54:18Z","timestamp":1540472058000},"page":"k4029","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":115,"title":["Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4114-8971","authenticated-orcid":false,"given":"Andrea C","family":"Tricco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wasifa","family":"Zarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areti-Angeliki","family":"Veroniki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Nincic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ghassemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane P","family":"Sharpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea V","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon E","family":"Straus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,10,25]]},"reference":[{"key":"key20190314145725_ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-015-1753-y"},{"key":"key20190314145725_ref2","first-page":"193","article-title":"Guidelines for the management of shingles. report of a working group of the British Society for the Study of Infection (BSSI)","volume":"30","year":"1995","journal-title":"J Infect"},{"key":"key20190314145725_ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(01)00044-5"},{"key":"key20190314145725_ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6532(03)00005-2"},{"key":"key20190314145725_ref5","doi-asserted-by":"publisher","DOI":"10.1067\/mgn.2000.108260"},{"key":"key20190314145725_ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-002-1053-2"},{"key":"key20190314145725_ref7","doi-asserted-by":"publisher","DOI":"10.4065\/82.11.1341"},{"key":"key20190314145725_ref8","doi-asserted-by":"publisher","DOI":"10.1086\/651078"},{"key":"key20190314145725_ref9","unstructured":"An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)- Update on the Use of Herpes Zoster Vaccine. 2014. www.canada.ca\/content\/dam\/phac-aspc\/documents\/services\/publications\/healthy-living\/update-use-herpes-zoster-vaccine\/hzv-vcz-eng.pdf."},{"key":"key20190314145725_ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051016"},{"key":"key20190314145725_ref11","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir970"},{"key":"key20190314145725_ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6532(10)70002-0"},{"key":"key20190314145725_ref13","first-page":"729","article-title":"Update on recommendations for use of herpes zoster vaccine","volume":"63","author":"Hales","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key20190314145725_ref14","unstructured":"SHINGRIX approved in Canada as the first non-live adjuvanted vaccine to help protect against shingles. 2017. http:\/\/ca.gsk.com\/en-ca\/media\/press-releases\/2017\/shingrix-approved-in-canada-as-the-first-non-live-adjuvanted-vaccine-to-help-protect-against-shingles\/."},{"key":"key20190314145725_ref15","unstructured":"GSK announces first approval of Shingrix in Canada- The only shingles vaccine to achieve \u226590% efficacy in adults aged 50 and over. GlaxoSmithKline, 2017."},{"key":"key20190314145725_ref16","unstructured":"Shingrix approved in the US for prevention of shingles in adults aged 50 and over- Pooled clinical trial results showed > 90 percent efficacy across all age groups, GlaxoSmithKline 2017."},{"key":"key20190314145725_ref17","unstructured":"Shingrix approved in Europe and Japan for the prevention of shingles in adults aged 50 and over- The only shingles vaccine to achieve \u226590% efficacy across all age groups studied*, GlaxoSmithKline 2018."},{"key":"key20190314145725_ref18","first-page":"CD008858","article-title":"Vaccines for preventing herpes zoster in older adults","volume":"3","author":"Gagliardi","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"key20190314145725_ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(97)00049-8"},{"key":"key20190314145725_ref20","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0.","author":"Higgins","year":"2011"},{"key":"key20190314145725_ref21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7647"},{"key":"key20190314145725_ref22","doi-asserted-by":"crossref","unstructured":"Tricco A, Zarin W, Cardoso R, et al. Efficacy, effectiveness, and safety of herpes zoster vaccines in individuals 50 years of age and older: a systematic review. PROSPERO 2017 CRD42017056389 www.crd.york.ac.uk\/PROSPERO\/display_record.php?ID=CRD42017056389.","DOI":"10.1136\/bmj.k4029"},{"key":"key20190314145725_ref23","doi-asserted-by":"publisher","DOI":"10.7326\/L15-5144-2"},{"key":"key20190314145725_ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.01.011"},{"key":"key20190314145725_ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.04.002"},{"key":"key20190314145725_ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.01.004"},{"key":"key20190314145725_ref27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092508"},{"key":"key20190314145725_ref28","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"key20190314145725_ref29","doi-asserted-by":"publisher","DOI":"10.1053\/apnr.2002.34181"},{"key":"key20190314145725_ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.01.021"},{"key":"key20190314145725_ref31","unstructured":"Matters G. a practical tool for searching health-related grey literature 2015 www.cadth.ca\/resources\/finding-evidence\/grey-matters."},{"key":"key20190314145725_ref32","unstructured":"Synthesi.SR [program]: Knowledge Translation Program."},{"key":"key20190314145725_ref33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"key20190314145725_ref34","unstructured":"Wells G, Shea B, O\u2019Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses."},{"key":"key20190314145725_ref35","unstructured":"EPOC Resources for review authors: Effective Practice and Organisation of Care (EPOC)."},{"key":"key20190314145725_ref36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2008.00347.x"},{"key":"key20190314145725_ref37","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dys041"},{"key":"key20190314145725_ref38","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5512"},{"key":"key20190314145725_ref39","unstructured":"ZOSTAVAX\u00ae II [product monograph] Canada: Merck Canada; 2017 https:\/\/pdf.hres.ca\/dpd_pm\/00042265.PDF2018."},{"key":"key20190314145725_ref40","unstructured":"SHINGRIX [product monograph] Canada: GlaxoSmithKline; 2017 https:\/\/ca.gsk.com\/media\/1350788\/shingrix_pm-2017-10-13.pdf2018."},{"key":"key20190314145725_ref41","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-159"},{"key":"key20190314145725_ref42","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1045"},{"key":"key20190314145725_ref43","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1044"},{"key":"key20190314145725_ref44","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7387.472"},{"key":"key20190314145725_ref45","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dys222"},{"key":"key20190314145725_ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.11.002"},{"key":"key20190314145725_ref47","unstructured":"CDC. Lesson 3: Measures of Risk: CDC; 2012 www.cdc.gov\/ophss\/csels\/dsepd\/ss1978\/lesson3\/section6.html accessed March 29, 2018."},{"key":"key20190314145725_ref48","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d549"},{"key":"key20190314145725_ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.016"},{"key":"key20190314145725_ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.02.016"},{"key":"key20190314145725_ref51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076654"},{"key":"key20190314145725_ref52","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00133-X"},{"key":"key20190314145725_ref53","doi-asserted-by":"publisher","DOI":"10.1086\/514265"},{"key":"key20190314145725_ref54","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit365"},{"key":"key20190314145725_ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.01.019"},{"key":"key20190314145725_ref56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603800"},{"key":"key20190314145725_ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.12.024"},{"key":"key20190314145725_ref58","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00310-07"},{"key":"key20190314145725_ref59","volume-title":"A phase III, randomised, open-label, multicentre, clinical trial to assess the safety and immunogenicity of GSK Biologicals\u2019 HZ\/su vaccine when administered intramuscularly according to a 0,2-month schedule, a 0,6- month schedule or a 0,12-month schedule in adults aged 50 years or older.","author":"GlaxoSmithKline Biologicals","year":"2016"},{"key":"key20190314145725_ref60","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13038"},{"key":"key20190314145725_ref61","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2007.01397.x"},{"key":"key20190314145725_ref62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501184"},{"key":"key20190314145725_ref63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001420"},{"key":"key20190314145725_ref64","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis497"},{"key":"key20190314145725_ref65","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv480"},{"key":"key20190314145725_ref66","doi-asserted-by":"publisher","DOI":"10.4161\/hv.6.11.12852"},{"key":"key20190314145725_ref67","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1016681"},{"key":"key20190314145725_ref68","first-page":"1","volume-title":"A Study to Evaluate Immunity to Varicella Zoster Virus After Immunization With V212 Vaccine or Zostavax (V212-003).","author":"Merck Sharp & Dohme Corp","year":"2015"},{"key":"key20190314145725_ref69","unstructured":"Murray A, Lawless J, Reisinger K, et al. Safety & Tolerability of Zoster Vaccine in Adults \u226560 Years Old. 2010. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00550745."},{"key":"key20190314145725_ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.04.090"},{"key":"key20190314145725_ref71","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw047"},{"key":"key20190314145725_ref72","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.10.027"},{"key":"key20190314145725_ref73","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.11.096"},{"key":"key20190314145725_ref74","doi-asserted-by":"publisher","DOI":"10.4161\/hv.23412"},{"key":"key20190314145725_ref75","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1232787"},{"key":"key20190314145725_ref76","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.7304"},{"key":"key20190314145725_ref77","unstructured":"GSK Clinical Study Register. A phase II, single-blind, randomized, controlled, multicentre vaccination study to evaluate the safety and immune response of the GSK Biologicals Zoster vaccine, gE\/AS01B, and to compare 3 doses of gE with AS01B adjuvant in healthy elderly subjects, aged 60 to 69 years and 70 years and above, 2010."},{"key":"key20190314145725_ref78","volume-title":"Ensayo cl\u00ednico de vacunaci\u00f3n fase III, aleatorizado, observador-ciego, controlado con placebo, multic\u00e9ntrico para evaluar la eficacia profil\u00e1ctica, seguridad e inmunogenicidad de la vacuna gE\/AS01B de GSK Biologicals administrada por v\u00eda intramuscular con.","author":"GlaxoSmithKline Biologicals","year":"2016"},{"key":"key20190314145725_ref79","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv432"},{"key":"key20190314145725_ref80","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis638"},{"key":"key20190314145725_ref81","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-152-9-201005040-00004"},{"key":"key20190314145725_ref82","doi-asserted-by":"publisher","DOI":"10.1086\/522159"},{"key":"key20190314145725_ref83","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2010.03021.x"},{"key":"key20190314145725_ref84","first-page":"1","article-title":"FDA Statistical Review and Evaluation Document for the Vaccines and Related Biological Products Advisory Committee (VRBPAC)","volume":"004","author":"Ahnn","year":"2005","journal-title":"Protocol"},{"key":"key20190314145725_ref85","doi-asserted-by":"publisher","DOI":"10.1086\/528696"},{"key":"key20190314145725_ref86","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-200510001-00151"},{"key":"key20190314145725_ref87","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit342"},{"key":"key20190314145725_ref88","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/cid\/civ930","article-title":"Effectiveness of Herpes Zoster Vaccine in Patients 60 Years and Older With End-stage Renal Disease","volume":"62","author":"Tseng","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key20190314145725_ref89","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1983"},{"key":"key20190314145725_ref90","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu498"},{"key":"key20190314145725_ref91","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis334"},{"key":"key20190314145725_ref92","unstructured":"Sanofi Pasteur MSDSNC. An open-label, randomised, phase 3, comparative, multi-centre study of the immunogenicity and safety of a 1-dose regimen and different 2-dose regimens of a Zoster vaccine (Live), ZOSTAVAX\u00ae, in subjects >=70 years of age, 2009:1-13. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00561080."},{"key":"key20190314145725_ref93","volume-title":"Safety and Immunogenicity Study of GSK Biologicals ' Herpes Zoster Subunit (HZ \/ su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged \u2265 50 Years.","author":"GlaxoSmithKline","year":"2017"},{"key":"key20190314145725_ref94","doi-asserted-by":"publisher","DOI":"10.1186\/ar3497"},{"key":"key20190314145725_ref95","doi-asserted-by":"publisher","DOI":"10.4161\/hv.7.11.17982"},{"key":"key20190314145725_ref96","unstructured":"Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds. ClinicalTrials.gov: U.S National Library of Medicine."},{"key":"key20190314145725_ref97","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6703a5"},{"key":"key20190314145725_ref98","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.10.067"},{"key":"key20190314145725_ref99","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2011.0724"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.k4029","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.k4029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T21:46:25Z","timestamp":1775252785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.k4029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,25]]},"references-count":99,"alternative-id":["10.1136\/bmj.k4029"],"URL":"https:\/\/doi.org\/10.1136\/bmj.k4029","relation":{},"ISSN":["0959-8138","1756-1833"],"issn-type":[{"value":"0959-8138","type":"print"},{"value":"1756-1833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,25]]}}}